Levi Strauss & Co. vs Viatris Inc — how do they compare? Levi Strauss & Co. trades at $23.97 (market cap $9.21B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 2.1× Levi Strauss & Co.'s market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| LEVI | VTRS | |
|---|---|---|
Market Cap | $9.21B | $19.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.99 | $17.39 |
52-Week Low | $17.92 | $8.74 |
Enterprise Value | $10.52B | $32.00B |
Dividend Yield | 2.68% | 2.83% |
Trailing returns across standard periods
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →